PEGylated versus non-PEGylated magnetic nanoparticles as camptothecin delivery system

被引:30
|
作者
Castillo, Paula M. [1 ,2 ,3 ]
de la Mata, Mario [4 ]
Casula, Maria F. [1 ,2 ]
Sanchez-Alcazar, Jose A. [4 ]
Zaderenko, Ana P. [3 ]
机构
[1] Univ Cagliari, INSTM, I-09124 Cagliari, Italy
[2] Univ Cagliari, Dipartimento Sci Chim & Geol, I-09124 Cagliari, Italy
[3] Univ Pablo Olavide, Dept Sistemas Fis Quim & Nat, Seville, Spain
[4] Univ Pablo Olavide, CSIC, CABD, Ctr Andaluz Biol Desarrollo, Seville, Spain
来源
关键词
camptothecin; cancer therapy; iron oxide superparamagnetic nanoparticles; polyethylene glycol; IRON-OXIDE NANOPARTICLES; DRUG-DELIVERY; IN-VIVO; CYCLODEXTRIN-COMPLEXATION; TOPOISOMERASE-I; CONTRAST AGENTS; THERAPY; PHASE; DESIGN; CYTOTOXICITY;
D O I
10.3762/bjnano.5.144
中图分类号
TB3 [工程材料学];
学科分类号
0805 ; 080502 ;
摘要
Camptothecin (CPT; (S)-(+)-4-ethyl-4-hydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14-(4H,12H)-dione) is a highly cytotoxic natural alkaloid that has not yet found use as chemotherapeutic agent due to its poor water-solubility and chemical instability and, as a consequence, no effective administration means have been designed. In this work, camptothecin has been successfully loaded into iron oxide superparamagnetic nanoparticles with an average size of 14 nm. It was found that surface modification of the nanoparticles by polyethylene glycol enables loading a large amount of camptothecin. While the unloaded nanoparticles do not induce apoptosis in the H460 lung cancer cell line, the camptothecin-loaded nanoparticle formulations exhibit remarkable proapoptotic activity. These results indicate that camptothecin retains its biological activity after loading onto the magnetic nanoparticles. The proposed materials represent novel materials based on naturally occurring bioactive molecules loaded onto nanoparticles to be used as chemotherapeutic formulations. The procedure seems apt to be extended to other active molecules extracted from natural products. In addition, these materials offer the potential of being further implemented for combined imaging and therapeutics, as magnetic nanoparticles are known to be multifunctional tools for biomedicine.
引用
收藏
页码:1312 / 1319
页数:8
相关论文
共 50 条
  • [41] Preclinical Studies of Pegylated- and Non-Pegylated Liposomal Forms of Doxorubicin as Radiosensitizer on Orthotopic High-Grade Glioma Xenografts
    Chastagner, P.
    Sudour, H.
    Mriouah, J.
    Barberi-Heyob, M.
    Bernier-Chastagner, V.
    Pinel, S.
    PHARMACEUTICAL RESEARCH, 2015, 32 (01) : 158 - 166
  • [42] Effectiveness of Pegylated Interferon Alpha-2a in Post-Uveitic Macular Edema Previously Responding to Non-Pegylated Interferon
    De Simone, L.
    Gentile, P.
    Aldigeri, R.
    Mastrofilippo, V.
    Bolletta, E.
    Gozzi, F.
    Adani, C.
    Salvarani, C.
    Cimino, L.
    OCULAR IMMUNOLOGY AND INFLAMMATION, 2024, 32 (05) : 678 - 682
  • [43] Impact of PEGylated Nanoparticles on Tumor Targeted Drug Delivery
    Mozar, Fitya Syarifa
    Chowdhury, Ezharul Hoque
    CURRENT PHARMACEUTICAL DESIGN, 2018, 24 (28) : 3283 - 3296
  • [44] Pegylated magnetic mesoporous silica nanoparticles decorated with AS1411 Aptamer as a targeting delivery system for cytotoxic agents
    Sakhtianchi, Ramin
    Darvish, Behrad
    Mirzaie, Zahra
    Dorkoosh, Farid
    Shanehsazzadeh, Saeed
    Dinarvand, Rassoul
    PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, 2019, 24 (09) : 1063 - 1075
  • [45] Pegylated poly(anhydride) nanoparticles for oral delivery of docetaxel
    Ruiz-Gaton, Luisa
    Espuelas, Socorro
    Larraneta, Eneko
    Reviakine, Ilya
    Yate, Luis A.
    Irache, Juan M.
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2018, 118 : 165 - 175
  • [46] Two phase II trials of temozolomide with interferon-α2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme
    M D Groves
    V K Puduvalli
    M R Gilbert
    V A Levin
    C A Conrad
    V H Liu
    K Hunter
    C Meyers
    K R Hess
    W K Alfred Yung
    British Journal of Cancer, 2009, 101 : 615 - 620
  • [47] Two phase II trials of temozolomide with interferon-α2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme
    Groves, M. D.
    Puduvalli, V. K.
    Gilbert, M. R.
    Levin, V. A.
    Conrad, C. A.
    Liu, V. H.
    Hunter, K.
    Meyers, C.
    Hess, K. R.
    Yung, W. K. Alfred
    BRITISH JOURNAL OF CANCER, 2009, 101 (04) : 615 - 620
  • [48] Pegylated and non-pegylated interferon-alfa and ribavirin for the treatment of mild chronic hepatitis C: A systematic review and meta-analysis
    Hartwell, Debbie
    Shepherd, Jonathan
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2009, 25 (01) : 56 - 62
  • [49] Synthesis and comparative in vivo evaluation of 99mTc(CO)3-labeled PEGylated and non-PEGylated cRGDfK peptide monomers
    Vats, Kusum
    Satpati, Drishty
    Sharma, Rohit
    Sarma, Haladhar D.
    Banerjee, Sharmila
    CHEMICAL BIOLOGY & DRUG DESIGN, 2017, 89 (03) : 371 - 378
  • [50] Neutrophils-mediated accelerated blood clearance phenomenon in beagles and rats based on the cross-injection of non-PEGylated and PEGylated nanoemulsions
    Liu, Mengyang
    Wang, Jia
    Chen, Ge
    Wang, Lirong
    Wang, Xuling
    Xiang, Bai
    Deng, Yihui
    He, Chaoxing
    Wang, Lei
    INTERNATIONAL JOURNAL OF PHARMACEUTICS-X, 2025, 9